2 Beaten-Down Stocks That Still Aren't Worth Buying
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
SRPT - Sarepta Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$24.78
DETAILS
HIGH:
$35.00
LOW:
$14.00
MEDIAN:
$25.00
CONSENSUS:
$24.78
UPSIDE:
30.77%
Stock News
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) into traditional approvals for Duchenne muscular dystrophy (DMD).
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administratio
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action data of February 28, 2027. The sNDA.
SRPT or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i.
My Top 3 Biotech Stocks for May 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presen.
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarept.
Price Targets
Sarepta price target lowered to $20 from $23 at Piper Sandler
$20.00
(was $20.21)
Piper Sandler
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
$27.00
(was $20.21)
Wolfe Research
Sarepta price target lowered to $19 from $20 at Evercore ISI
$19.00
(was $18.20)
Evercore ISI
Deutsche ups Sarepta target, says 35% stock rally overdone
$14.00
(was $21.68)
Deutsche Bank
Sarepta price target raised to $35 from $29 at Wedbush
$35.00
(was $21.68)
Wedbush
Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho
$31.00
(was $17.04)
Uy Ear
·
Mizuho Securities
Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets
$25.00
(was $15.87)
Ilya Zubkov
·
Loop Capital Markets
Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
$30.00
(was $15.98)
Andrew Tsai
·
Jefferies
Sarepta price target raised to $22 from $15 at Baird
$22.00
(was $22.80)
Robert W. Baird
Wedbush bullish on Sarepta, initiates with an Outperform
$32.00
(was $21.86)
Wedbush
Sarepta price target raised to $20 from $18 at Bernstein
$20.00
(was $18.91)
Bernstein
Sarepta price target lowered to $20 from $22 at Barclays
$20.00
(was $16.20)
Barclays
Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform
$26.00
(was $16.20)
Uy Ear
·
Mizuho Securities
Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird
$15.00
(was $24.45)
Brian Skorney
·
Robert W. Baird
Sarepta price target raised to $16 from $15 at Piper Sandler
$16.00
(was $23.45)
Biren Amin
·
Piper Sandler
Sarepta price target raised to $15 from $12 at Leerink
$15.00
(was $17.57)
Joseph Schwartz
·
Leerink Partners
Sarepta debt refinancing eases liquidity concerns, says Barclays
$22.00
(was $20.06)
Barclays
Sarepta price target raised to $12 from $6 at Deutsche Bank
$12.00
(was $20.30)
David Hoang
·
Deutsche Bank
Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight
$18.00
(was $13.32)
Gena Wang
·
Barclays
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)
$50.00
(was $14.07)
Kostas Biliouris
·
BMO Capital